Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

March 20, 2023

Study Completion Date

December 1, 2023

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).

Trial Locations (13)

110060

Sir Ganga Ram Hospital, New Delhi

380054

Shalby Hospital, Ahmedabad

380060

Healthcare Center Global Hospital, Ahmedabad

400012

Tata Memorial Hospital, Mumbai

400026

Jaslok Hospital and Research Centre, Mumbai

400071

Sushrut Hospital & Research Centre, Mumbai

400078

Fortis Hospital, West-Mumbai

411001

Jehangir Hospital, Pune

500096

Apollo Research Foundation, Hyderabad

625020

Apollo Speciality Hospitals, Madurai

700020

IPGME & R / SSKM Hospital, Kolkata

700025

Health Point Hospital, Kolkata

751007

Sparsh Hospital & Critical Care, Bhubaneswar

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03564938 - Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). | Biotech Hunter | Biotech Hunter